PSMD8

Across TCGA pan-cancer cohorts, PSMD8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMD8 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PSMD8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMD8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, LUAD, and COAD are the cancer types where PSMD8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.348	0.884	.001	30	view →
LUAD	OS	Median	All	0.605	0.903	<.001	25	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
UCEC	OS	Median	All	0.983	0.839	.005	6	view →
CCRCC	OS	Quartile	All	0.730	0.914	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMD8–PDAC (DFS)

Open the PDAC breakdown →